{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/prescribing-information/furosemide/","result":{"pageContext":{"chapter":{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide","depth":2,"htmlHeader":"<!-- begin field 583670ce-7a8e-436c-96b7-5beff2278338 --><h2>Furosemide</h2><!-- end field 583670ce-7a8e-436c-96b7-5beff2278338 -->","summary":"","htmlStringContent":"<!-- begin item 8633d636-f7f1-4b87-9da7-c4f31072fd31 --><!-- begin field 7859914b-89dd-47d1-b118-e4fc6a0ed58b --><ul><li>The use of furosemide for the treatment of nocturnal polyuria in men is off label [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">NICE, 2010</a>].</li></ul><!-- end field 7859914b-89dd-47d1-b118-e4fc6a0ed58b --><!-- end item 8633d636-f7f1-4b87-9da7-c4f31072fd31 -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"cf19617f-02dd-58e4-a01e-0ece1e830d48","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field c3de64cd-c17a-4a6f-8e22-249ae64585f1 --><h3>What are the contraindications and cautions for furosemide?</h3><!-- end field c3de64cd-c17a-4a6f-8e22-249ae64585f1 -->","summary":"","htmlStringContent":"<!-- begin item 5af9e788-d6c7-4087-8e9f-1e69b4059b63 --><!-- begin field d1e04863-1162-4c46-be1a-3f02185c9cf8 --><ul><li><strong>Do not use furosemide in people with:</strong><ul><li>Anuria.</li><li>Comatose and precomatose states associated with liver cirrhosis.</li><li>Renal failure due to nephrotoxic or hepatotoxic drugs. </li><li>Severe hyponatraemia or hypokalaemia.</li><li>Hypovolaemia and dehydration (with or without accompanying hypotension).</li><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 mL/minute/1.73 m<sup>2</sup>).</li><li>Addison's disease.</li><li>Digitalis intoxication.</li><li>Porphyria.</li></ul></li><li><strong>Use furosemide with caution in:</strong><ul><li>People with:<ul><li>Hypotension — correct before starting furosemide, and monitor blood pressure.</li><li>Hypovolaemia or acute hypercalcaemia — correct before starting furosemide.</li><li>Diabetes mellitus — furosemide could worsen glucose control.</li><li>Gout — electrolyte imbalance caused by furosemide may aggravate gout.</li><li>Prostatic enlargement or impaired micturition — furosemide may worsen urinary flow.</li><li>Mild to moderate renal impairment — higher doses may be needed. However, large doses can cause deafness.</li><li>Hepatic impairment — hypokalaemia may precipitate coma in people with severe liver disease.</li><li>Adrenal disease.</li><li>Hypoproteinaemia, for example nephrotic syndrome — the effect of furosemide may be impaired and its ototoxicity potentiated. Cautious dose titration is required.</li></ul></li><li>Elderly people — furosemide is excreted more slowly in the elderly. Treatment should be started with 20 mg and titrated upwards as required.</li><li>People who are at risk from a pronounced fall in blood pressure.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016b</a>]</p><!-- end field d1e04863-1162-4c46-be1a-3f02185c9cf8 --><!-- end item 5af9e788-d6c7-4087-8e9f-1e69b4059b63 -->","subChapters":[]},{"id":"c9721bc2-cef4-5e02-b62f-ffe0a3eb6463","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field bdba3bd3-a9e2-4b6a-b1b4-cd96417d1d49 --><h3>What dose of furosemide should I prescribe?</h3><!-- end field bdba3bd3-a9e2-4b6a-b1b4-cd96417d1d49 -->","summary":"","htmlStringContent":"<!-- begin item 6a2c2590-56fe-484c-8eff-fffe178d104f --><!-- begin field ed44d696-152f-40cd-b99b-015cdec01df8 --><ul><li><strong>CKS recommends prescribing 20–40 mg of furosemide once a day.</strong><ul><li>In elderly people, treatment should be started with 20 mg and titrated upwards as required, as furosemide is excreted more slowly in the elderly. </li></ul></li><li>Although the use of furosemide is off label for men with nocturnal polyuria, these doses are consistent with those recommended for people who have oedema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>].</li></ul><!-- end field ed44d696-152f-40cd-b99b-015cdec01df8 --><!-- end item 6a2c2590-56fe-484c-8eff-fffe178d104f -->","subChapters":[]},{"id":"cf313cdb-f7f9-5be7-bcad-6df42a433e35","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 92f32e0d-1c58-4359-93ee-aba319e2e8df --><h3>What are the adverse effects of furosemide?</h3><!-- end field 92f32e0d-1c58-4359-93ee-aba319e2e8df -->","summary":"","htmlStringContent":"<!-- begin item 8dcf9f26-a914-4fdd-9a40-63ba26e0a60a --><!-- begin field 61090492-e6ea-4c92-aa2e-241e666c96e7 --><ul><li><strong>Excessive diuresis can cause orthostatic hypotension, dehydration, renal dysfunction, and electrolyte imbalances.</strong><ul><li>If there is evidence of symptomatic hypotension (low blood pressure plus dizziness, light-headedness, or confusion), consider steps to counteract this, for example reduce the dose of furosemide or any concurrent drugs known to reduce blood pressure.</li><li>Titrate the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/furosemide/#dose\">dose</a> of furosemide up or down according to the person's symptoms. Use the lowest possible dose to control symptoms.</li><li>Monitor renal function and serum electrolytes regularly, especially after increasing the dose of furosemide or adding an <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/furosemide/#drug-interactions\">interacting drug</a>.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>For all loop diuretics:<ul><li>Common or very common — fatigue, headache, metabolic alkalosis, muscle spasms, and nausea.</li><li>Uncommon — diarrhoea.</li><li>Rare or very rare — bone marrow depression and photosensitivity reaction.</li><li>Frequency not known — deafness, leucopenia, paraesthesia, rash, severe cutaneous adverse reactions (SCARs), thrombocytopenia, tinnitus (more common in renal impairment), and vomiting.</li></ul></li><li>In addition for furosemide:<ul><li>Frequency not known — acute pancreatitis, acute kidney injury, agranulocytosis, aplastic anaemia, diabetes mellitus, eosinophilia, fever, gout, haemolytic anaemia, hepatic encephalopathy, malaise, metabolic acidosis, mucosal reaction, nephritis tubulointerstitial, psychiatric disorder, shock, skin eruption, tetany, urinary disorders, and vasculitis.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 61090492-e6ea-4c92-aa2e-241e666c96e7 --><!-- end item 8dcf9f26-a914-4fdd-9a40-63ba26e0a60a -->","subChapters":[]},{"id":"c4e40ec8-923b-5ebd-aa74-2812d8b989a6","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0c639511-05ce-4bd4-85f3-283b1fbee6b6 --><h3>What are the key drug interactions of furosemide?</h3><!-- end field 0c639511-05ce-4bd4-85f3-283b1fbee6b6 -->","summary":"","htmlStringContent":"<!-- begin item 8afe8192-96fd-47eb-9c23-6b7526b23dbc --><!-- begin field d67bc9c5-95d7-4454-adfb-ae27822f7c48 --><ul><li><strong>Drug interactions of furosemide include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li><strong>Cardiac glycosides </strong>— hypokalaemia and electrolyte disturbances (including hypomagnesia) increase the risk of digoxin toxicity.<ul><li>Manufacturer advises caution.</li></ul></li><li><strong>Drugs that cause hypotension </strong>—<strong> </strong>an additive hypotensive effect may occur during concurrent use with furosemide and other drugs that can cause hypotension, such as angiotensin converting enzyme (ACE) inhibitors, beta-blockers, calcium channel blockers, other diuretics, and nitrates.</li><li><strong>Drugs that cause </strong><strong>hypokalaemia</strong> — an additive hypokalaemic effect may occur during concurrent use with furosemide and other drugs that can cause hypokalaemia, such as thiazide diuretics, reboxetine, and fluconazole.</li><li><strong>Drugs known to prolong the QT interval </strong>— furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with drugs known to prolong the QT interval,  including antiarrhythmics (such as amiodarone), tricyclic antidepressants, macrolide antibiotics, and antipsychotics (such as amisulpride  and pimozide).<ul><li>Avoid concurrent use with pimozide.</li></ul></li><li><strong>Drugs that cause hyponatraemia </strong>— an additive hyponatraemic effect may occur during concurrent use with furosemide and drugs that can cause hyponatraemia, such as desmopressin, tricyclic antidepressants, selective serotonin reuptake inhibitors, chlorpromazine, and carbamazepine.<ul><li>Avoid concurrent use with desmopressin due to increased risk of hyponatraemia.</li></ul></li><li><strong>Lithium </strong>— furosemide reduces lithium excretion, leading to an increased risk of lithium toxicity.<ul><li>Monitor concurrent use and adjust dose.</li></ul></li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— NSAIDs may antagonize the diuretic effect of furosemide and increase the risk of nephrotoxicity.</li></ul></li><li><strong>For a complete list of possible drug interactions of furosemide, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><!-- end field d67bc9c5-95d7-4454-adfb-ae27822f7c48 --><!-- end item 8afe8192-96fd-47eb-9c23-6b7526b23dbc -->","subChapters":[]},{"id":"c8b6be2d-afa0-56a1-86b8-573b00384e08","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 11f4b598-dad8-45b1-8b43-cce3d6996f3b --><h3>How should I monitor a person taking furosemide?</h3><!-- end field 11f4b598-dad8-45b1-8b43-cce3d6996f3b -->","summary":"","htmlStringContent":"<!-- begin item 8ef4ef5c-9928-401e-918e-93105f74f809 --><!-- begin field ebbb1144-86ac-4802-bfef-646f7fe6cc27 --><ul><li><strong>Measure renal function and serum electrolytes before starting furosemide treatment.</strong></li><li><strong>Check renal function and serum electrolytes (noting potassium levels):</strong><ul><li>Within 1–2 weeks after starting treatment and after each dose increase. Earlier monitoring (within 5–7 days) may be required in higher-risk people (including people with existing renal impairment and people on combination therapy).</li><li>If the person's clinical condition changes or a potential <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/furosemide/#drug-interactions\">interacting drug</a> is added.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">Smellie et al, 2007</a>]</p><!-- end field ebbb1144-86ac-4802-bfef-646f7fe6cc27 --><!-- end item 8ef4ef5c-9928-401e-918e-93105f74f809 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}